The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Melphalan chemosaturation with percutaneous hepatic ...

The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as ...

This case highlights the need for immunohistochemical profiling of patients with multiple breast nodules and a history of ...

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host ...

Final results from the Phase II CONCEPT trial reveal that isatuximab combined with carfilzomib, lenalidomide, and ...

A comparison of melphalan and prednisone with/without bortezomib in untreated myeloma patients ineligible for high-dose therapy plus stem-cell transplantation was investigated. What were the outcomes?

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

Sidebar Key Issues. Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma.. Advanced disease and extramedullary involvement are common clinical ...